Patents Assigned to BRISTOL-MYERS QUIBB COMPANY
  • IP-10 antibodies and their uses
    Patent number: 11708405
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: July 25, 2023
    Assignee: BRISTOL-MYERS QUIBB COMPANY
    Inventors: Mohan Srinivasan, Shrikant Deshpande, Qihong Zhao, Huadong Sun, Ginger Rakestraw, Guodong Chen, Richard Y. Huang, Steven Sheriff, Cristian Rodriguez, John P. Throup, Rose A. Dibella
  • Inhibitors of type 2 vascular endothelial growth factor receptors
    Patent number: 9862758
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: January 9, 2018
    Assignee: BRISTOL-MYERS QUIBB COMPANY
    Inventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind